Pharsight

Drugs that contain Bictegravir Sodium; Emtricitabine; Tenofovir Alafenamide Fumarate

1. Biktarvy patents expiration

BIKTARVY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7390791 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(1 year, 4 months from now)

US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(8 years from now)

US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(8 years from now)

US9216996 GILEAD SCIENCES INC Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections
Dec, 2033

(10 years from now)

US9732092 GILEAD SCIENCES INC Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections
Dec, 2033

(10 years from now)

US9708342 GILEAD SCIENCES INC Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate
Jun, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7803788 GILEAD SCIENCES INC Prodrugs of phosphonate nucoleotide analogues
Feb, 2022

(1 year, 9 months ago)

US7390791

(Pediatric)

GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Oct, 2025

(1 year, 10 months from now)

US8754065

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(9 years from now)

US9296769

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(9 years from now)

US10385067 GILEAD SCIENCES INC Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate
Jun, 2035

(11 years from now)

US11744802 GILEAD SCIENCES INC Therapeutic compositions for treatment of human immunodeficiency virus
Nov, 2036

(12 years from now)

US10548846 GILEAD SCIENCES INC Therapeutic compositions for treatment of human immunodeficiency virus
Nov, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 7, 2023
Orphan Drug Exclusivity (ODE) Oct 7, 2028
M (M) Feb 24, 2024

NCE-1 date: 2022-02-07

Market Authorisation Date: 07 February, 2018

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of BIKTARVY before it's drug patent expiration?
More Information on Dosage

BIKTARVY family patents

Family Patents